CR10997A - Metodo de tratamiento de canceres - Google Patents

Metodo de tratamiento de canceres

Info

Publication number
CR10997A
CR10997A CR10997A CR10997A CR10997A CR 10997 A CR10997 A CR 10997A CR 10997 A CR10997 A CR 10997A CR 10997 A CR10997 A CR 10997A CR 10997 A CR10997 A CR 10997A
Authority
CR
Costa Rica
Prior art keywords
treatment method
cancer treatment
dichichi
peptid
agonist
Prior art date
Application number
CR10997A
Other languages
English (en)
Inventor
Lynn Erickson-Miller Connie
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CR10997A publication Critical patent/CR10997A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se inventa un metodo para tratar canceres y sindromes precancerosos en un mamifero, incluyendo a un ser humano, que lo necesita, que comprende la administracion de una cantidad terapeuticamente eficaz de un agonista no peptidico del receptor de TPO a dichi mamifero.
CR10997A 2007-02-16 2009-08-26 Metodo de tratamiento de canceres CR10997A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03

Publications (1)

Publication Number Publication Date
CR10997A true CR10997A (es) 2009-10-16

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10997A CR10997A (es) 2007-02-16 2009-08-26 Metodo de tratamiento de canceres

Country Status (28)

Country Link
US (2) US20100075928A1 (es)
EP (1) EP2124547B3 (es)
JP (1) JP5511391B2 (es)
KR (1) KR101447763B1 (es)
CN (1) CN101662937B (es)
AR (1) AR065348A1 (es)
AU (1) AU2008216106C1 (es)
BR (1) BRPI0807940B8 (es)
CA (1) CA2678358C (es)
CR (1) CR10997A (es)
DK (1) DK2124547T6 (es)
EA (1) EA017715B1 (es)
ES (1) ES2675070T7 (es)
FI (1) FI2124547T4 (es)
HU (1) HUE038563T2 (es)
IL (2) IL200319A (es)
MA (1) MA31202B1 (es)
MX (1) MX2009008822A (es)
NZ (1) NZ579068A (es)
PE (1) PE20081784A1 (es)
PL (1) PL2124547T5 (es)
PT (1) PT2124547T (es)
SI (1) SI2124547T2 (es)
TR (1) TR201809010T4 (es)
TW (1) TW200906393A (es)
UY (1) UY30915A1 (es)
WO (1) WO2008101141A2 (es)
ZA (1) ZA200905532B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
SG176088A1 (en) 2009-05-29 2011-12-29 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
BR112013004714A2 (pt) * 2010-09-01 2016-05-17 Novartis Ag "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN118453872A (zh) * 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
CN1376150A (zh) * 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
EP1227843B1 (en) * 1999-11-10 2009-10-14 BioPheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6887890B2 (en) * 2000-05-30 2005-05-03 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
JP2004503217A (ja) * 2000-05-31 2004-02-05 ジェンザイム・コーポレーション 卵巣癌のための治療化合物
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
MXPA03006510A (es) 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
JP4120586B2 (ja) * 2002-01-18 2008-07-16 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (ja) 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
EP1622609A4 (en) 2003-04-29 2008-09-03 Smithkline Beecham Corp METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2583764C (en) * 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.

Also Published As

Publication number Publication date
NZ579068A (en) 2012-05-25
UY30915A1 (es) 2008-09-02
EA017715B1 (ru) 2013-02-28
SI2124547T2 (sl) 2025-07-31
ES2675070T7 (en) 2025-08-06
WO2008101141A3 (en) 2008-10-16
HUE038563T2 (hu) 2018-10-29
AR065348A1 (es) 2009-06-03
CN101662937B (zh) 2014-03-12
AU2008216106C1 (en) 2025-11-13
EP2124547B1 (en) 2018-03-28
JP2010519221A (ja) 2010-06-03
PT2124547T (pt) 2018-07-04
ZA200905532B (en) 2010-04-28
CN101662937A (zh) 2010-03-03
US20100075928A1 (en) 2010-03-25
AU2008216106B2 (en) 2013-07-11
MX2009008822A (es) 2009-08-28
DK2124547T4 (da) 2025-08-04
EP2124547A2 (en) 2009-12-02
EP2124547B3 (en) 2025-06-18
IL238394A0 (en) 2015-06-30
EA200970776A1 (ru) 2010-02-26
FI2124547T4 (fi) 2025-07-29
PL2124547T3 (pl) 2018-08-31
DK2124547T6 (da) 2025-09-01
PL2124547T5 (pl) 2025-08-04
BRPI0807940B8 (pt) 2021-05-25
EP2124547A4 (en) 2010-05-05
CA2678358C (en) 2015-12-08
BRPI0807940A2 (pt) 2013-07-30
WO2008101141A2 (en) 2008-08-21
DK2124547T3 (en) 2018-07-16
MA31202B1 (fr) 2010-02-01
JP5511391B2 (ja) 2014-06-04
IL200319A (en) 2015-05-31
BRPI0807940B1 (pt) 2020-10-27
IL238394B (en) 2018-05-31
TW200906393A (en) 2009-02-16
PE20081784A1 (es) 2009-01-25
ES2675070T3 (es) 2018-07-06
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
KR101447763B1 (ko) 2014-10-07
AU2008216106B9 (en) 2013-09-05
SI2124547T1 (en) 2018-08-31
EP2124547B2 (en) 2025-04-16
TR201809010T4 (tr) 2018-07-23
IL200319A0 (en) 2010-04-29
AU2008216106A1 (en) 2008-08-21
CA2678358A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
CR10997A (es) Metodo de tratamiento de canceres
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
GT200900182A (es) Inhibidores de la poli (adp-ribosa) polimerasa
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
UY30492A1 (es) Anticuerpo antagonista para el tratamiento del cancer
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
EA201300411A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
CL2008001626A1 (es) Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
PA8849001A1 (es) Anticuerpos de c-met
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
AR092219A1 (es) Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
CL2008002506A1 (es) Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer.
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)